Effectiveness of haemophilus influenzae type b conjugate vaccine for prevention of meningitis in senegal

Pediatric Infectious Disease Journal

Volumn 30, Issue 5, 2011, Pages 430-432

  Fleming, Jessica A ^a   Dieye, Yakou ^b   Ba, Ousseynou ^b   Mutombo Wa Mutombo, Boniface ^b   Diallo, Ndiouga ^b   Faye, Pape Coumba ^c   Ba, Mamadou ^d   Cisse, Moussa Fafa ^d   Diallo, Aissatou Gaye ^e   Ba, Mady ^c   Slack, Mary P E ^f   Weiss, Noel S ^g  

^a PATH   (United States)

^b PATH   (Senegal)

^c Senegal Ministry of Health   (Senegal)

^d Albert Royer Hospital   (Senegal)

^e Centre Hospitalier Universitaire Aristide Le Dantec de Dakar   (Senegal)

^f PUBLIC HEALTH ENGLAND   (United Kingdom)

^g UNIVERSITY OF WASHINGTON   (United States)

Author keywords

bacterial meningitis; Haemophilus influenzae type b; Haemophilus influenzae type b conjugate vaccine; Senegal; vaccine effectiveness

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; ORAL POLIOMYELITIS VACCINE;

ARTICLE; CHILD; CLINICAL ARTICLE; CONJUGATE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HAEMOPHILUS INFLUENZAE TYPE B; HAEMOPHILUS MENINGITIS; HEALTH PROGRAM; HUMAN; INFANT; MALE; PRESCHOOL CHILD; PREVENTIVE MEDICINE; PRIORITY JOURNAL; SENEGAL;

EID: 79954826846     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e318203aaa0     Document Type: Article

References (16)

1. World Health Organization. WHO position paper on Haemophilus influen-zae type b conjugate vaccines. Wkly Epidemiol Rec. 2006;81:445-452.
2. Mulholland K, Hilton S, Adegbola R, et al. Randomised trial of Haemo-philus influenzae type-b tetanus protein conjugate vaccine [corrected] for prevention of pneumonia and meningitis in Gambian infants. Lancet. 1997;349:1191-1197. (Pubitemid 27190041)
3. Adegbola RA, Secka O, Lahai G, et al. Elimination of Haemophilus influenzae type b disease from The Gambia after the introduction of routine immunisation with a Hib conjugate vaccine: a prospective study. Lancet. 2005;366:144-150. (Pubitemid 40991215)
4. Cowgill KD, Ndiritu M, Nyiro J, et al. Effectiveness of Haemophilus influenzae type b conjugate vaccine introduction into routine childhood immunization in Kenya. JAMA. 2006;296:671-678. (Pubitemid 44200638)
5. von Gottberg A, de Gouveia L, Madhi SA, et al. Impact of conjugate Haemophilus influenzae type b (Hib) vaccine introduction in South Africa. Bull World Health Organ. 2006;84:811-818. (Pubitemid 44610116)
6. Otten MW, Soriano-Gabarró M, Shaba K, et al. Hib-Paediatric Bacterial Meningitis (Hib-PBM) Surveillance Network: Surveillance Manual, Field Test Version, July 2001. Harare, Zimbabwe: World Health Organization Regional Office for Africa; 2001.
7. Ba O, Fleming J, Dieye Y, et al. Hospital surveillance ofchildhood bacterial meningitis in Senegal and the introduction of Haemophilus influenzae type b conjugate vaccine. Am J Trop Med Hyg. In press.
8. Orenstein WA, Bernier RH, Dondero TJ, et al. Field evaluation ofvaccine efficacy. Bull Word Health Organ. 1985;63:1055-1068.
9. Lee EH, Lewis RF, Makumbi I, et al. Haemophilus influenzae type b conjugate vaccine is highly effective in the Ugandan routine immunization program: a case-control study. Trop Med Int Health. 2008;13:495-502. (Pubitemid 351533600)
10. Daza P, Banda R, Misoya K, et al. The impact ofroutine infant immuni-zation with Haemophilus influenzae type b conjugate vaccine in Malawi, a country with high human immunodeficiency virus prevalence. Vaccine. 2006;24:6232-6239. (Pubitemid 44262417)
11. Peltola H. Worldwide Haemophilus influenzae type b disease at the begin-ning ofthe 21st century: global analysis ofthe disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev. 2000;13:302-317 (Pubitemid 30205428)
12. World Health Organization. Haemophilus influenzae type b (Hib) menin-gitis in the pre-vaccine era: a global review of incidence, age distributions, and case-fatality rates. WHO/V&B/02.18. Geneva: World Health Organi-zation Department of Vaccines and Biologicals; 2002.
13. World Health Organization. Aide-memoire for prevention offreeze damage to vaccines. WHO/IVB/07.09. Geneva: World Health Organization Depart-ment ofImmunization, Vaccines and Biologicals; 2007.
14. World Health Organization. Training for Mid-Level Managers (MLM); Module 1: Cold chain, Vaccines and Safe Injection Equipment Manage-ment WHO/IVB/08.01. Geneva: World Health Organization Department of Immunization, Vaccines and Biologicals; 2008.
15. Grover A, Singh A. Validity ofthe shake test to identify the frozen damaged vaccine vials. Indian Pediatr. 2005;42:724-725. (Pubitemid 41039687)
16. Howie SR, Antonio M, Akisanya A, et al. Re-emergence of Haemophilus influenzae type b (Hib) disease in The Gambia following successful elim-ination with conjugate Hib vaccine. Vaccine. 2007;25:6305-6309. (Pubitemid 47088758)